
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
SFXN5 (sideroflexin 5) encodes a mitochondrial protein predicted to function as a citrate transmembrane transporter. It is predicted to participate in citrate transport and mitochondrial transmembrane transport. SFXN5 is relevant to studies of mitochondrial metabolite transport and cellular metabolic processes.
Y79 is a human retinoblastoma cell line established from a primary tumor of the right eye of a 2.5-year-old female patient. The cells grow in clusters, exhibit reverse transcriptase activity, and carry a partial deletion of the RB1 gene. Y79 is used as a model for studying retinoblastoma biology, retinal tumor development, and RB1-related cancer mechanisms.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Knockout Region: E2
Reference Transcript: SFXN5-201
Validation Method: PCR amplification+Sanger sequencing
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?